Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andes-1537 in Advanced Solid Tumors
NCT03985072Phase 1Completed
- Sponsor
- Andes Biotechnologies
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of andes-1537 in gallbladder cancer, biliary tract cancer (BTC), Cervical Cancer (CC) and 3 more (5 cohorts), sponsored by Andes Biotechnologies. Primary endpoint: Incidence of treatment-emergent adverse events at 24 weeks. Started Apr 2019; status: completed.
02
Drugs
andes-1537
03
Conditions
gallbladder cancerbiliary tract cancer (BTC)Cervical Cancer (CC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03985072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985072.